Convalescent plasma and COVID‐19: Time for a second—second look?
In this short narrative, we highlight some of our experiences leading the US Convalescent
Plasma Program at the beginning of the pandemic in the spring and summer of 2020. This …
Plasma Program at the beginning of the pandemic in the spring and summer of 2020. This …
Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality
Background: The US Food and Drug Administration authorized COVID-19 convalescent
plasma (CCP) therapy for hospitalized COVID-19 patients via the Expanded Access …
plasma (CCP) therapy for hospitalized COVID-19 patients via the Expanded Access …
Development and validation of a treatment benefit index to identify hospitalized patients with COVID-19 who may benefit from convalescent plasma
Importance Identifying which patients with COVID-19 are likely to benefit from COVID-19
convalescent plasma (CCP) treatment may have a large public health impact. Objective To …
convalescent plasma (CCP) treatment may have a large public health impact. Objective To …
A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia
Background Antibody-based strategies for COVID-19 have shown promise in prevention
and treatment of early disease. COVID-19 convalescent plasma (CCP) has been widely …
and treatment of early disease. COVID-19 convalescent plasma (CCP) has been widely …
The Journal of Clinical Investigation in the time of COVID-19
A Casadevall, S Jackson, GL Semenza… - The Journal of …, 2021 - Am Soc Clin Investig
In this editorial, we describe the experience of the JCI editors during the COVID-19
pandemic. Our goal is to share how we operated during the pandemic, recount how the JCI …
pandemic. Our goal is to share how we operated during the pandemic, recount how the JCI …
[HTML][HTML] Convalescent plasma use in the United States was inversely correlated with COVID-19 mortality: did plasma hesitancy cost lives?
Background. The US Food and Drug Administration authorized Convalescent Plasma (CCP)
therapy for hospitalized COVID-19 patients via the Expanded Access Program (EAP) and …
therapy for hospitalized COVID-19 patients via the Expanded Access Program (EAP) and …
Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality
C Arturo, D Quigly, PW Johnson, JW Senefeld… - eLife, 2021 - search.proquest.com
Background: The US Food and Drug Administration authorized COVID-19 convalescent
plasma (CCP) therapy for hospitalized COVID-19 patients via the Expanded Access …
plasma (CCP) therapy for hospitalized COVID-19 patients via the Expanded Access …
COVID-19 convalescent plasma and randomized clinical trials: explaining conflicting outcomes and finding signals of efficacy
Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is
available as soon as there are survivors. The COVID-19 pandemic represented the first …
available as soon as there are survivors. The COVID-19 pandemic represented the first …
[PDF][PDF] Expanded Access and Emergency Use Authorization: COVID-19 Indian scenario
B More, A More - wwjmrd.com
Globally, the development, review, and approval process of novel medicinal products is a
time consuming and costly affair. The new drug has to face several reviews and scrutiny …
time consuming and costly affair. The new drug has to face several reviews and scrutiny …